Updates are available Correction dated 2024-07-08
Click to view Correction: https://doi.org/10.1038/s41467-024-50151-0
-
Authors
Copland, Emma https://orcid.org/0000-0001-9280-5241
Patone, Martina
Saatci, Defne https://orcid.org/0000-0002-2414-2906
Handunnetthi, Lahiru
Hirst, Jennifer
Hunt, David P. J. https://orcid.org/0000-0003-4230-0207
Mills, Nicholas L. https://orcid.org/0000-0003-0533-7991
Moss, Paul https://orcid.org/0000-0002-6895-1967
Sheikh, Aziz https://orcid.org/0000-0001-7022-3056
Coupland, Carol A. C.
Harnden, Anthony
Robertson, Chris https://orcid.org/0000-0001-6848-5241
Hippisley-Cox, Julia https://orcid.org/0000-0002-2479-7283
-
Funding
Funding for this research was provided by:
NIHR School for Primary Care Research (SPCR), grant reference number: 622
- License Information
-
More Information
Article History
Received: 17 June 2023
Accepted: 11 April 2024
First Online: 27 May 2024
Change Date: 8 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-50151-0
Competing interests
: J.H.C. reports grants from National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, John Fell Oxford University Press Research Fund, Cancer Research UK and Oxford Wellcome Institutional Strategic Support Fund and other research councils, during the conduct of the study outside the scope of this work. J.H.C. is founder and was shareholder until 9 Aug 2023 of ClinRisk Ltd, which produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. J.H.C. is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health who supply the QResearch database used for this work and is a consultant for Endeavour Predict Ltd outside this work. A.S. serves on a number of UK and Scottish Government COVID-19 advisory groups and was a member of AstraZeneca’s Thrombotic Thrombocytopenic Taskforce; all roles are unremunerated. A.H. is Deputy Chair of the Joint Committee on Vaccination and Immunisation. D.H. serves on the UK Government Commission on Human Medicines P.M. has received speaker and advisory board fees from Moderna and Astra Zeneca. All other authors declare no competing interests related to this paper.
